Celldex Therapeutics, Inc.
NCM: CLDXLive Quote
📈 ZcoreAI Score
Our AI model analyzes Celldex Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get CLDX Z-Score →About Celldex Therapeutics, Inc.
Healthcare
Biotechnology
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
📊 Fundamental Analysis
Celldex Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -89.7% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -40.6%, which indicates that capital utilization is currently under pressure.
At a current price of $32.24, CLDX currently trades near the top of its 52-week range (87%) (Range: $16.74 - $34.52).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$2.53B
Trailing P/E
--
Forward P/E
-6.77
Beta (5Y)
1.20
52W High
$34.52
52W Low
$16.74
Avg Volume
1.00M
Day High
Day Low